Abstract
Bevacizumab (Avastin®) is a vascular endothelial growth factor (VEGF)-specific molecular drug. It effectiveness was first reported in 2003 by the American Society of Clinical Oncology, and it has been used in Japan since 2007. Bevacizumab used in combination with cytotoxic agents has shown antitumor activity in several types of cancer, particularly in metastatic colorectal cancer (mCRC). We report the pharmacological effects of this drug, reviews of clinical trials, and outcomes in our hospital.
